Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma

Clinical and Translational Oncology

Volumn 15, Issue 11, 2013, Pages 919-924

  Pedicini, P ^a   Fiorentino, A ^a   Improta, G ^a   Nappi, A ^a   Salvatore, M ^b   Storto, G ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b IRCCS SDN   (Italy)

Author keywords

Accelerated proliferation; Doubling time; PTEN expression; Radiosensitivity

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; PREDICTIVE VALUE; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION;

ALGORITHMS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE PROGRESSION; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RADIATION INJURIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84886595505     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1024-2     Document Type: Article

References (30)

1. Overgaard J, Alsner J, Eriksen J, Horsman MR, Grau C. Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays. 2000;25:313-9.
2. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933-40. (Pubitemid 37159288)
3. Hansen O, Overgaard J, Hansen HS, Overgaard M, Höyer M, Jörgensen KE, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumour differentiation. Radiother Oncol. 1997;43:47-51. (Pubitemid 27191978)
4. Dassonville O, Forment JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11:1873-8. (Pubitemid 23304610)
5. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumour differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2004;58:561-6. (Pubitemid 38142484)
6. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005;23:5560-7.
7. Suwinski R, Jaworska M, Nikiel B, Grzegorz W, Bankowska-Wozniak M, Wojciech M, et al. Predicting the effect of accelerated fractionation in postoperative radiotherapy for head and neck cancer based on molecular marker profiles: data from a randomized clinical trial. Int J Radiat Oncol Biol Phys. 2010;77:438-46.
8. Chung CH, Zhang Q, Hammond EM, Trotti AM 3rd, Wang H, Spencer S, et al. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:331-8.
9. Snietura M, Jaworska M, Mlynarczyk Liszka J, Goraj-Zajac A, Piglowski W, Lange D, et al. PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS One. 2012;7:e33396.
10. Pedicini P, Strigari L, Benassi M. Estimation of a self consistent set of radiobiological parameters from hypofractionated versus standard radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2013; doi:10.1016/j.ijrobp. 2012.11.033.
11. Pedicini P, Nappi A, Strigari L, Alicia Jereczek-Fossa B, Alterio D, Cremonesi M, et al. Correlation between EGFR expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol. 2012;7:143.
12. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Timedose factors in radiotherapy: a review of the human data. Radiother Oncol. 1990;19:219-35. (Pubitemid 20369216)
13. Bentzen SM, Johansen LV, Overgaard J, Thames HD. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 1991;20:1197-206.
14. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-46.
15. Robertson C, Robertson AG, Hendry JH, Roberts SA, Slevin NJ, Duncan WB, et al. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centres. Int J Radiat Oncol Biol Phys. 1998;40:319-29. (Pubitemid 28114375)
16. Thames HD, Rozell ME, Tucker SL, Ang KK, Fisher DR, Travis EL. Direct analysis of quantal radiation response data. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;49:999-1009. (Pubitemid 16036970)
17. Collett D. Modelling survival data-in medical research. London (UK): Chapman and Hall; 1994.
18. Barendsen GW. Dose fractionation, dose rate and isoeffect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:779-90.
19. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, et al. Genetic variant in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012;18:3705-13.
20. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133:403-14. (Pubitemid 351622014)
21. Wang X, Jiang X. PTEN: a default gate-keeping tumor suppressor with a versatile tail. Cell Res. 2008;18:807-16.
22. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation induced EGFr nuclear import by C225 (Cetuximab) suppresses DNA PK activity. Radiother Oncol. 2005;76:157-61. (Pubitemid 41725442)
23. Begg AC, Vens C. Genetic manipulation of radiosensitivity. Int J Radiat Oncol Biol Phys. 2001;49:367-71. (Pubitemid 32120233)
24. Pedicini P, Caivano R, Jereczek-Fossa BA, Strigari L, Vischioni B, Alterio D, et al. Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors. Theol Biol Med Mod. 2012;9:23.
25. Steel GG. Cell loss as a factor in the growth rate of human tumours. Eur J Cancer. 1967;3:381-7.
26. Trott K. The mechanisms of acceleration of repopulation in squamous epithelia during daily irradiation. Acta Oncol. 1999;38:153-7. (Pubitemid 29179768)
27. Marcu L, Van Doorn T, Olver I. Modelling of post-irradiation accelerated repopulation in squamous cell carcinoma. Phys Med. 2004;49:3767-79. (Pubitemid 39206456)
28. Bernier J, Horiot JC. Altered-fractionated radiotherapy in locally advanced head and neck cancer. Curr Opin Oncol. 2012;24:223-8.
29. Pedicini P, Caivano R, Strigari L, Benassi M, Fiorentino A, Fusco V. In regard to Miralbell et al. Int J Radiat Oncol Biol Phys. 2013;85:10-1.
30. Fiorentino A, Cozzolino M, Caivano R, Pedicini P, Chiumento C, Oliviero C, et al. Cone-beam computed tomography dose monitoring during intensitymodulated radiotherapy in head and neck cancer: parotid glands. Clin Transl Oncol. 2012;. doi:10.1007/s1209401209464.